Department of Physical Medicine and Rehabilitation, 499996Shuang Ho Hospital, Taipei Medical University, Taipei.
Department of Physical Medicine and Rehabilitation, Wan Fang Hospital, Taipei Medical University, Taipei.
Clin Rehabil. 2022 Jun;36(6):740-752. doi: 10.1177/02692155221086213. Epub 2022 Mar 8.
This study assessed the effectiveness, compliance, and safety of dextrose prolotherapy for patients with knee osteoarthritis.
PubMed, EMBASE, the Cochrane Library Database, and the Scopus database from their inception to December 31, 2021.
This study was conducted in accordance with the guidelines recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Randomized controlled trials regarding the effectiveness of dextrose prolotherapy in knee osteoarthritis were identified. The included trials were subjected to meta-analysis. Risk of bias was assessed using the Cochrane risk of bias tool. Subgroup and random-effects metaregression analyses were performed to explore any heterogeneity () of treatment effects across studies.
A total of 14 trials enrolling 978 patients were included in the meta-analysis. Compared with placebo injection and noninvasive control therapy, dextrose prolotherapy had favorable effects on pain, global function, and quality of life during the overall follow-up. Dextrose prolotherapy yielded greater reductions in pain score over each follow-up duration than did the placebo. Compared with other invasive therapies, dextrose prolotherapy generally achieved comparable effects on pain and functional outcomes for each follow-up duration.Subgroup results indicated that combined intra-articular and extra-articular injection techniques may have stronger effects on pain than a single intra-articular technique.
Dextrose prolotherapy may have dose-dependent and time-dependent effects on pain reduction and function recovery, respectively, in patients with knee osteoarthritis. Due to remarkable heterogeneity and the risk of biases across the included trials, the study results should be cautiously interpreted.
本研究评估了葡萄糖水疗法治疗膝骨关节炎患者的有效性、依从性和安全性。
PubMed、EMBASE、Cochrane 图书馆数据库和 Scopus 数据库,检索时间截至 2021 年 12 月 31 日。
本研究按照系统评价和荟萃分析首选报告项目的指南进行。确定了关于葡萄糖水疗法治疗膝骨关节炎有效性的随机对照试验。对纳入的试验进行荟萃分析。使用 Cochrane 偏倚风险工具评估纳入研究的偏倚风险。进行亚组和随机效应荟萃回归分析,以探索研究间治疗效果的异质性()。
共有 14 项试验纳入 978 例患者进行荟萃分析。与安慰剂注射和非侵入性对照治疗相比,葡萄糖水疗法在整体随访期间对疼痛、整体功能和生活质量均有较好的疗效。葡萄糖水疗法在每个随访时间点的疼痛评分降低幅度均大于安慰剂。与其他侵入性治疗相比,葡萄糖水疗法在每个随访时间点的疼痛和功能结局方面通常具有相当的效果。亚组结果表明,关节内和关节外联合注射技术可能比单一关节内技术对疼痛有更强的效果。
葡萄糖水疗法可能对膝骨关节炎患者的疼痛减轻和功能恢复分别具有剂量依赖性和时间依赖性的作用。由于纳入的试验存在显著的异质性和偏倚风险,研究结果应谨慎解释。